GENE ONLINE|News &
Opinion
Blog

2025-11-27|

Study Identifies Stage-Dependent Cognitive Network Changes in Early Psychosis

by GOAI
Share To

Researchers have identified stage-dependent patterns of cognitive network connectivity in individuals experiencing early psychosis, revealing complex neural changes associated with the onset of psychotic disorders. The study, conducted by Tang, Wei, and Pang, highlights distinct phases of cognitive network transformations that occur during the early stages of these conditions. Published in *Nature Communications* in 2025, the findings provide detailed insights into how brain connectivity evolves during this critical period.

The research analyzed cognitive networks to determine how connectivity shifts across different stages of early psychosis. By examining these changes, the study aimed to better understand the neurological processes underlying psychotic disorders as they develop. The results indicate that specific alterations in brain connectivity are linked to different phases of early psychosis progression. These findings contribute to a growing body of knowledge about the neural mechanisms involved in psychotic disorders and may inform future approaches to diagnosis and treatment.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 28, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top